Ciccocioppo Rachele, Cangemi Giuseppina C, Kruzliak Peter, Gallia Alessandra, Betti Elena, Badulli Carla, Martinetti Miryam, Cervio Marila, Pecci Alessandro, Bozzi Valeria, Dionigi Paolo, Visai Livia, Gurrado Antonella, Alvisi Costanza, Picone Cristina, Monti Manuela, Bernardo Maria E, Gobbi Paolo, Corazza Gino R
Clinica Medica I, Dipartimento di Medicina Interna, Fondazione IRCCS Policlinico San Matteo, Università di Pavia, Piazzale Golgi 19, Pavia, 27100, Italy.
Centre for the Study and Cure of Inflammatory Bowel Disease, Clinica Medica I, IRCCS San Matteo Hospital Foundation, University of Pavia, Piazzale Golgi 19, Pavia, 27100, Italy.
Stem Cell Res Ther. 2015 Jul 24;6(1):137. doi: 10.1186/s13287-015-0122-1.
Crohn's disease (CD) is a disabling chronic enteropathy sustained by a harmful T-cell response toward antigens of the gut microbiota in genetically susceptible subjects. Growing evidence highlights the safety and possible efficacy of mesenchymal stem cells (MSCs) as a new therapeutic tool for this condition. Therefore, we aimed to investigate the effects of bone marrow-derived MSCs on pathogenic T cells with a view to clinical application.
T-cell lines from both inflamed and non-inflamed colonic mucosal specimens of CD patients and from healthy mucosa of control subjects were grown with the antigen muramyl-dipeptide in the absence or presence of donors' MSCs. The MSC effects were evaluated in terms of T-cell viability, apoptotic rate, proliferative response, immunophenotype, and cytokine profile. The role of the indoleamine 2,3-dioxygenase (IDO) was established by adding a specific inhibitor, the 1-methyl-DL-tryptophan, and by using MSCs transfected with the small interfering RNA (siRNA) targeting IDO. The relevance of cell-cell contact was evaluated by applying transwell membranes.
A significant reduction in both cell viability and proliferative response to muramyl-dipeptide, with simultaneous increase in the apoptotic rate, was found in T cells from both inflamed and non-inflamed CD mucosa when co-cultured with MSCs and was reverted by inhibiting IDO activity and expression. A reduction of the activated CD4(+)CD25(+) subset and increase of the CD3(+)CD69(+) population were also observed when T-cell lines from CD mucosa were co-cultured with MSCs. In parallel, an inhibitory effect was evident on the expression of the pro-inflammatory cytokines tumor necrosis factor-α, interferon-γ, interleukin-17A and -21, whereas that of the transforming growth factor-β and interleukin-6 were increased, and production of the tolerogenic molecule soluble HLA-G was high. These latter effects were almost completely eliminated by blocking the IDO, whose activity was upregulated in MSCs co-cultured with CD T cells. The use of a semipermeable membrane partially inhibited the MSC immunosuppressive effects. Finally, hardly any effects of MSCs were observed when T cells obtained from control subjects were used.
MSCs exert potent immunomodulant effects on antigen-specific T cells in CD through a complex paracrine and cell-cell contact-mediated action, which may be exploited for widespread therapeutic use.
克罗恩病(CD)是一种致残性慢性肠病,由基因易感个体中针对肠道微生物群抗原的有害T细胞反应所引发。越来越多的证据表明,间充质干细胞(MSCs)作为治疗这种疾病的一种新的治疗工具具有安全性和可能的疗效。因此,我们旨在研究骨髓来源的MSCs对致病性T细胞的影响,以期用于临床。
将来自CD患者发炎和未发炎结肠黏膜标本以及对照受试者健康黏膜的T细胞系与抗原胞壁酰二肽一起培养,培养过程中有无供体MSCs。从T细胞活力、凋亡率、增殖反应、免疫表型和细胞因子谱等方面评估MSCs的作用。通过添加特异性抑制剂1-甲基-DL-色氨酸以及使用转染靶向吲哚胺2,3-双加氧酶(IDO)的小干扰RNA(siRNA)的MSCs来确定IDO的作用。通过应用Transwell膜评估细胞间接触的相关性。
与MSCs共培养时,来自发炎和未发炎CD黏膜的T细胞的细胞活力和对胞壁酰二肽的增殖反应均显著降低,同时凋亡率增加,而抑制IDO活性和表达可使其恢复。当CD黏膜的T细胞系与MSCs共培养时,还观察到活化的CD4(+)CD25(+)亚群减少,CD3(+)CD69(+)群体增加。同时,对促炎细胞因子肿瘤坏死因子-α、干扰素-γ、白细胞介素-17A和-21的表达有明显抑制作用,而转化生长因子-β和白细胞介素-6的表达增加,并且耐受性分子可溶性HLA-G的产生较高。通过阻断IDO,这些后期效应几乎完全消除,IDO的活性在与CD T细胞共培养的MSCs中上调。使用半透膜部分抑制了MSCs的免疫抑制作用。最后,当使用从对照受试者获得的T细胞时,几乎未观察到MSCs的任何作用。
MSCs通过复杂的旁分泌和细胞间接触介导的作用对CD中的抗原特异性T细胞发挥强大的免疫调节作用,这可能被广泛用于治疗。